OXFORD - Shire Pharmaceuticals Group plc (LSE:SHP) and partner Janssen Pharmaceutica NV on Saturday presented positive data from a U.S. Phase III trial of SHP's galantamine for Alzheimer's disease. If the results hold up to FDA scrutiny, SHP would be positioned with one of the few effective treatments for AD.

The results also reinforce SHP's status as Britain's leading entrepreneurial life sciences company and most likely candidate to break away from the U.K. biotech pack (see Ebb & Flow, A9).